In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment till ailment progression or maybe the members are not able to tolerate the study drugs. - "Our study discovered the vital part of the KLF16/MYC regulatory axis https://keikoy211lvf3.qodsblog.com/profile